Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
NCT00585689Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2007
- Primary completion
- Apr 2013
- Countries
- 1
- Sponsor
- University of Michigan Rogel Cancer Center
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Drugs
- nab-paclitaxel
- Conditions
- bladder cancer
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in bladder cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Complete Pathologic Response at 63 days. Started Dec 2007; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Neoadjuvant ABI-007, Carboplatin, and Gemcitabine
Experimental arm receiving 3 cycles of neoadjuvant ABI-007, carboplatin, and gemcitabine prior to radical cystectomy.
03
Who it enrols
Patients with locally advanced urothelial carcinoma of the bladder who are candidates for cystectomy, have adequate organ function, ECOG PS 0-2, and no prior systemic chemotherapy or radiotherapy.
04
Endpoints
Primary
Complete Pathologic Response
Beyond the preview
Go deeper on NCT00585689.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585689.